The Safety of 2-(3-BROMO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE

Introduction

2-(3-Bromo-phenyl)-imidazo[1,2-a]pyrimidine (CAS 16670-19-4) is a synthetic chemical compound that has been widely used in various applications in the chemical industry.
This compound belongs to a class of molecules known as imidazo[1,2-a]pyrimidines, which have been studied extensively for their potential as anti-inflammatory, anti-allergic, and anti-cancer agents.
However, the use of this compound and its derivatives has also raised concerns about their potential toxicity and safety.

Chemical Structure and Properties

The chemical structure of 2-(3-bromo-phenyl)-imidazo[1,2-a]pyrimidine consists of a bromo-substituted phenyl group (-Br) attached to an imidazo[1,2-a]pyrimidine ring system.
The imidazo[1,2-a]pyrimidine ring system is composed of a six-membered ring with an imidazo[1,2-a]pyrimidine nitrogen atom (-N=) attached to two carbon atoms and a third carbon atom forming a double bond with the phenyl group (-C=C-).
This chemical structure confers a number of physical and chemical properties to the compound, including its solubility in water and organic solvents, its relatively low melting and boiling points, and its potential to form adducts with nucleophiles such as glutathione.

Toxicity Studies

To assess the potential toxicity of 2-(3-bromo-phenyl)-imidazo[1,2-a]pyrimidine, a number of in vivo and in vitro toxicity studies have been conducted using various species, including rats, mice, and hamsters.
In general, these studies have reported a wide range of results, with some studies suggesting that the compound may be relatively safe at low doses, while others have reported evidence of toxicity and potential health hazards at higher doses.

For example, one study reported that oral administration of 2-(3-bromo-phenyl)-imidazo[1,2-a]pyrimidine to rats at doses of up to 50 mg/kg body weight for 90 days resulted in no significant adverse effects, while higher doses of 100 and 200 mg/kg body weight caused histopathological changes in the liver and other organs (1).
However, another study reported that oral administration of the compound to mice at doses of 10 and 100 mg/kg body weight caused significant decreases in body weight and increases in liver weight, as well as histopathological changes in the liver and other organs (2).

In vitro toxicity studies have also reported a range of results.
For example, one study reported that 2-(3-bromo-phenyl)-imidazo[1,2-a]pyrimidine caused significant cytotoxicity in a human cancer cell line (HeLa) at concentrations above 10 μM, while another study reported that the compound was relatively non-toxic to a variety of cells, including liver and kidney cells, at concentrations up to 100 μM (3, 4).

Epidemiological Studies

Epidemiological studies are another important tool for assessing the potential health hazards of chemicals.
However, there are currently no published epidemiological studies specifically focused on 2-(3-bromo-phenyl)-imidazo[1,2-a]pyrimidine.
This is likely due to the fact that the compound is not widely used in the general population and is primarily used in research and development settings.

Phys